2 The technologies
2.1 Ten epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation methods for identifying adults with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC) who may benefit from first-line treatment with EGFR‑TK inhibitors were evaluated. Three are CE‑marked tests; 5 are laboratory-developed tests; and 2 are test strategies combining a CE‑marked test and a laboratory-developed test. Additional details of the tests are provided in section 4.
2.2 Other tests and methods for detecting EGFR‑TK mutations are available, such as MALDI‑TOF. NICE is aware that the tests and methods are evolving, so new ones are likely to appear in the future.